095sek
1,1 %
Date:2024-04-26Time:17:29:52Latest report:Q4-2023List:First NorthTicker:ELIC
Market Cap:33 msekEnterprise Value:4 msekNet Sales:- msekEarnings:-16,4 msekEmployees:0ISIN:SE0015382080

Ratios

10-year key figure history for Elicera Therapeutics turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Elicera Therapeutics with index and moving average MA50 and MA200.

Stockprice:0,95
MA50:1,46
MA200:3,09
Price/MA200:-69,2 %
RSI (14):23,2
Price/MA50:-34,8 %

Description

Elicera Therapeutics AB is a clinical phase immunooncology company that develops cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, of which two in the field of oncolytic viruses and two in the field of CAR T-cell treatments, as well as a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune boosting in treatment in the said field.

Pharmaceuticals